Skip to main content

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

MarginProbe® System U.S. Post-Approval Study

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about MarginProbe® System U.S. Post-Approval Study

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Registry of Guardant360® Use and Outcomes In People With Advanced Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Registry of Guardant360® Use and Outcomes In People With Advanced Cancer

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 89
  • Page 90
  • Page 91
  • Page 92
  • Page 93
  • Page 94
  • Page 95
  • Page 96
  • Page 97
  • …
  • Next page Next
  • Last page Last
Subscribe to